A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Registration Number
- NCT04657302
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This study will evaluate the pharmacokinetics, safety, tolerability, and efficacy of glofitamab as a single agent following a fixed single dose of obinutuzumab in Chinese patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have failed two or more lines of systemic therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Histologically-confirmed DLBCL
- Participants must have relapsed or failed to respond to at least two lines of prior systemic therapy (including at least one prior regimen containing anthracycline, and at least one containing an anti-CD20-directed therapy)
- Participants must have measurable disease: at least one bi-dimensionally measurable nodal lesion, defined as > 1.5 cm in its longest dimension; or at least one bi-dimensionally measurable extranodal lesion, defined as > 1.0 cm in its longest dimension
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 1 or 1
- Adverse events from prior anti-cancer therapy must have resolved to Grade </=1
- Adequate liver, hematological, and renal function
- Negative serum pregnancy test within 7 days prior to study treatment in women of childbearing potential
- Women of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use contraception as defined by the protocol, and agree to refrain from donating eggs during the treatment period and for at least 18 months after the final dose of obinutuzumab, 2 months after the final dose of glofitamab, and 3 months after the final dose of tocilizumab (if applicable)
- Men must agree to remain abstinent (refrain from heterosexual intercourse) or use contraception as defined by the protocol, and agree to refrain from donating sperm during the treatment period and for at least 3 months after the final dose of obinutuzumab, 4 months after the final dose of glofitamab, and 2 months after the final dose of tocilizumab (if applicable)
- Reside in the People's Republic of China
Exclusion Criteria
- Richter's transformation
- Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection within 4 weeks prior to first study treatment
- Suspected or latent tuberculosis
- Positive for HIV, hepatitis C (HCV), or hepatitis B (HBV)
- Known or suspected chronic active Epstein-Barr virus infection
- Known or suspected history of hemaphagocytic lymphohistiocytosis (HLH)
- Prior treatment with systemic immunotherapeutic agents
- History of treatment-emergent immune-related adverse events associated with prior immunotherapeutic agents
- Documented refractoriness to an obinutuzumab monotherapy-containing regimen
- Treatment with standard radiotherapy, any chemotherapeutic agent, including CAR T therapy
- Prior solid organ or allogenic stem cell transplantation
- Autologous stem cell transplantation within 100 days prior to obinutuzumab infusion
- Active autoimmune disease requiring treatment
- History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
- History of confirmed progressive multifocal leukoencephalopathy (PML)
- Current or past history of CNS lymphoma
- Current or past history of central nervous system (CNS) disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
- Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including diabetes mellitus, history of relevant pulmonary disorders, and known autoimmune diseases
- Major surgery or significant traumatic injury < 28 days prior to obinutuzumab infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment
- Another invasive malignancy in the last 2 years
- Significant cardiovascular disease
- Administration of a live, attenuated vaccine within 4 weeks before obinutizumab infusion, or anticipation that one will be required during the study
- Systemic immunosuppresive medications
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description R/R DLBCL Obinutuzumab Participants will receive a fixed dose of obinutuzumab pre-treatment followed by glofitamab on Cycle 1 Days 8 and 15, then every 3 weeks (Q3W) from Cycles 2-12 (cycle length = 21 days). R/R DLBCL Glofitamab Participants will receive a fixed dose of obinutuzumab pre-treatment followed by glofitamab on Cycle 1 Days 8 and 15, then every 3 weeks (Q3W) from Cycles 2-12 (cycle length = 21 days). R/R DLBCL Tocilizumab Participants will receive a fixed dose of obinutuzumab pre-treatment followed by glofitamab on Cycle 1 Days 8 and 15, then every 3 weeks (Q3W) from Cycles 2-12 (cycle length = 21 days).
- Primary Outcome Measures
Name Time Method Percentage of Participants with Adverse Events (AEs) Up to 3.5 years Serum Concentration of Glofitamab At pre-defined intervals up to 3.5 years Total Exposure (AUC) of Glofitamab At pre-defined intervals up to 3.5 years Maximum Serum Concentration (Cmax) of Glofitamab At pre-defined intervals up to 3.5 years Minimum Serum Concentration (Cmin) of Glofitamab At pre-defined intervals up to 3.5 years Clearance of Glofitamab At pre-defined intervals up to 3.5 years Volume of Distribution at Steady State (Vss) of Glofitamab At pre-defined intervals up to 3.5 years Half-life (T1/2) of Glofitamab At pre-defined intervals up to 3.5 years Complete Response Rate (CRR) as Assessed by an Independent Review Committee (IRC) Up to 3.5 years Percentage of Participants with Anti-Drug Antibodies (ADA) Up to 3.5 years
- Secondary Outcome Measures
Name Time Method Investigator-Assessed CRR Up to 3.5 years Duration of Complete Response (CR) as Assessed by IRC and Investigator Up to 3.5 years Objective Response Rate (ORR) as Assessed by IRC Up to 3.5 years ORR as Assessed by Investigator Up to 3.5 years Duration of Objective Response (DOR) as Assessed by IRC and Investigator Up to 3.5 years Progression-Free Survival (PFS) as Determined by IRC and Investigator Up to 3.5 years Overall Survival (OS) Up to 3.5 years Time to First Overall Response (TFOR) as Assessed by IRC and Investigator Up to 3.5 years Time to First Complete Response (TFCR) as Assessed by IRC and Investigator Up to 3.5 years
Trial Locations
- Locations (6)
Tianjin Cancer Hospital
🇨🇳Tianjin, China
Cancer Center, Sun Yat-sen University of Medical Sciences; Department of Medical Oncology
🇨🇳Guangzhou City, China
Beijing Cancer Hospital
🇨🇳Beijing, China
Peking University Third Hospital
🇨🇳Beijing, China
Harbin Medical University Cancer Hospital
🇨🇳Harbin, China
Jiangsu Province Hospital
🇨🇳Nanjing, China